Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy
Authors:
Open Access
- 15 April 2022
- journal article
- research article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 54 (2) , 362-374
Abstract
PurposeThe purpose of this study was to optimize a peptide (nABP284) that binds to programmed cell death protein 1 (PD-1) by a computer-based protocol in order to increase its affinity. Then, this study aimed to determine the inhibitory effects of this peptide on cancer immune escape by coculturing improving cytokine-induced killer (ICIK) cells with cancer cells.Materials and MethodsnABP284 that binds to PD-1 was identified by phage display technology in our previous study. AutoDock and PyMOL were used to optimize the sequence of nABP284 to design a new peptide (nABPD1). Immunofluorescence was used to demonstrate that the peptides bound to PD-1. Surface plasmon resonance was used to measure the binding affinity of the peptides. The blocking effect of the peptides on PD-1 was evaluated by a neutralization experiment with human recombinant programmed death-ligand 1 (PD-L1) protein. The inhibition of activated lymphocytes by cancer cells was simulated by coculturing of human acute T lymphocytic leukemia cells (Jurkat T cells) with human tongue squamous cell carcinoma cells (Cal27 cells). The anticancer activities were determined by coculturing ICIK cells with Cal27 cells in vitro.ResultsA high-affinity peptide (nABPD1, KD=11.9 nM) for PD-1 was obtained by optimizing the nABP284 peptide (KD=11.8 μM). nABPD1 showed better efficacy than nABP284 in terms of increasing the secretion of interkeulin-2 by Jurkat T cells and enhancing the in vitro antitumor activity of ICIK cells.ConclusionnABPD1 possesses higher affinity for PD-1 than nABP284, which significantly enhances its ability to block the PD-1/PD-L1 interaction and to increase ICIK cell-mediated antitumor activity by armoring ICIK cells.Keywords
Funding Information
- Chinese Ministry of Science and Technology (2014AA020702)
- Guangdong Provincial Department of Science and Technology (2016B030231001, 2017B020230002)
This publication has 30 references indexed in Scilit:
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular CarcinomaGastroenterology, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Overcoming T cell exhaustion in infection and cancerTrends in Immunology, 2015
- Peptide therapeutics: current status and future directionsDrug Discovery Today, 2015
- Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast CancerClinical Cancer Research, 2014
- Structure and Interactions of the Human Programmed Cell Death 1 ReceptorJournal of Biological Chemistry, 2013
- Acidity Generated by the Tumor Microenvironment Drives Local InvasionCancer Research, 2013
- Peptides as Targeting Elements and Tissue Penetration Devices for NanoparticlesAdvanced Materials, 2012
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008